18.59 USD
↗ 0.40 (2.20%)AT CLOSE (11:59 AM EDT)
Zenas BioPharma, Inc. Common Stock
ZBIONASDAQ • USD
18.57
↘ 0.02 (0.10%)
POST MARKET (AS OF 07:41 PM EDT)
Post Market
AS OF 07:41 PM EDT
18.57
↘ 0.02 (0.10%)
Market: CLOSED
Open?$18.04
High?$19.04
Low?$17.90
Prev. Close?$18.19
Volume?344.5K
Avg. Volume?868.1K
VWAP?$18.54
Rel. Volume?0.40x
Bid / Ask
Bid?$15.55 × 100
Ask?$21.78 × 100
Spread?$6.23
Midpoint?$18.67
Valuation & Ratios
Market Cap?1.1B
Shares Out?57.4M
Float?14.3M
Float %?26.6%
P/E Ratio?N/A
P/B Ratio?4.69
EPS?-$6.06
Dividend?0.00%
Ex-Dividend?N/A
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?5.61Strong
Quick Ratio?5.61Strong
Cash Ratio?1.77Strong
Debt/Equity?0.32Low
ValuationFAIRLY VALUED
Score58/100
P/E?N/A▾
P/B?4.69FAIR▾
P/S?113.45HIGH▾
P/FCF?N/A▾
EV/EBITDA?-2.9CHEAP▾
EV/Sales?110.25HIGH▾
Returns & Efficiency
ROE?-156.0%WEAK▾
ROA?-98.5%WEAK▾
Cash Flow & Enterprise
FCF?$-172351000
Enterprise Value?$1.1B
Fundamentals ratios updated end of day
xxx
Related Companies
Loading...
News
Profile
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company manages its operations on a consolidated basis as a single reportable segment focused on the research, development and commercialization of transformative immunology-based therapies.
Employees
167
Market Cap
1.1B
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2024-09-13
Address
852 WINTER STREET, SUITE 250
WALTHAM, MA 02451
Phone: 857-271-2954
WALTHAM, MA 02451
Phone: 857-271-2954